Literature DB >> 14657842

Atopic dermatitis and the atopic march.

Jonathan M Spergel1, Amy S Paller.   

Abstract

Atopic dermatitis (AD), one of the most common skin disorders seen in infants and children, usually has its onset during the first 6 months of life. The prevalence of AD is similar in the United States, Europe, and Japan and is increasing, similar to that of other atopic disorders, particularly asthma. AD has been classified into 3 sequential phases: infantile, childhood, and adult, each with characteristic physical findings. AD has a tremendously negative effect on the quality of life of patients as well as family, most commonly disturbing sleep. The condition also creates a great financial burden for both the family and society. The cutaneous manifestations of atopy often represent the beginning of the atopic march. On the basis of several longitudinal studies, approximately half of AD patients will develop asthma, particularly with severe AD, and two thirds will develop allergic rhinitis. Epicutaneous sensitization has been thought to be responsible, with subsequent migration of sensitized T cells into the nose and airways, causing upper and lower airway disease. Animal models and human observation concur with this theory. Preliminary prevention studies with oral antihistamines provide evidence that early intervention might slow the atopic march.

Entities:  

Mesh:

Year:  2003        PMID: 14657842     DOI: 10.1016/j.jaci.2003.09.033

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  263 in total

1.  The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients.

Authors:  Xingnan Li; Elizabeth J Ampleford; Timothy D Howard; Wendy C Moore; Huashi Li; William W Busse; Mario Castro; Serpil C Erzurum; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; W Gerald Teague; Sally E Wenzel; Gregory A Hawkins; Eugene R Bleecker; Deborah A Meyers
Journal:  J Allergy Clin Immunol       Date:  2011-11-08       Impact factor: 10.793

2.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

Review 3.  Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of 'atopic dermatitis'.

Authors:  R Kantor; J P Thyssen; A S Paller; J I Silverberg
Journal:  Allergy       Date:  2016-08-03       Impact factor: 13.146

4.  Predicting eczema severity beyond childhood.

Authors:  Kam Lun Hon; Yin-Ching K Tsang; Terence Chuen W Poon; Nga Hin Pong; Matthew Kwan; Shirley Lau; Yuen-Chun Chiu; Hin-Hei Wong; Ting-Fan Leung
Journal:  World J Pediatr       Date:  2015-12-18       Impact factor: 2.764

Review 5.  Epidermal barrier formation and recovery in skin disorders.

Authors:  Julia A Segre
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Accident and emergency: a gateway to improve the management of atopic disease.

Authors:  S Treffene; R Paget; I Maconochie
Journal:  Arch Dis Child       Date:  2006-06       Impact factor: 3.791

Review 7.  Lessons from murine models of atopic dermatitis.

Authors:  Tao Zheng; Zhou Zhu
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.806

Review 8.  Animal models of atopic dermatitis.

Authors:  Haoli Jin; Rui He; Michiko Oyoshi; Raif S Geha
Journal:  J Invest Dermatol       Date:  2009-01       Impact factor: 8.551

9.  MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells.

Authors:  L Ma; H-B Xue; F Wang; C-M Shu; J-H Zhang
Journal:  Clin Exp Immunol       Date:  2015-05-25       Impact factor: 4.330

10.  The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch.

Authors:  Sarah R Wilson; Lydia Thé; Lyn M Batia; Katherine Beattie; George E Katibah; Shannan P McClain; Maurizio Pellegrino; Daniel M Estandian; Diana M Bautista
Journal:  Cell       Date:  2013-10-03       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.